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Carbapenems have long been a reliable last line of 
defence in the treatment of infections caused by 
antimicrobial-resistant Enterobacteriaceae. However, 
the emergence of resistance in Enterobacteriaceae 
mediated via carbapenemases is a major public 
health concern as these isolates show resistance to antibiotics 
commonly used to treat Gram-negative infections.[1] Furthermore, 
these highly resistant strains have been shown to have the propensity 
to spread rapidly.[2] A large variety of carbapenemases belonging to 
3 classes of β-lactamases have been identified in Enterobacteriaceae: 
the Ambler class A, B and D β-lactamases. Carbapenem resistance 
as a result of Klebsiella pneumoniae carbapenemase (KPC; Class A), 
New Delhi metallo-beta-lactamase-1 (NDM-1; Class B) and OXA- 
subtypes (Class D) are thought to occur at low levels in Africa.[1]
The first case of NDM-1 carbapenem resistance in South Africa 
(SA) occurred in August 2011[3] and was reported from a hospital 
in Johannesburg. The first documented case of NDM-1-producing 
Enterobacteriaecae in KwaZulu-Natal (KZN), SA, is reported here and 
documents a direct epidemiological link to the Indian subcontinent.
Method and results
Case report
A 61-year-old woman presented to her general practitioner on 2 
November 2012 for removal of a urinary catheter. She had been 
hospitalised in India from 21 to 24 October for management of a 
fractured femur. Antibiotics administered intra-operatively included 
cephalosporins and amikacin. Of note, urine submitted on admission 
to the hospital in India revealed no abnormalities. She was discharged 
on cefuroxime axetil 500 mg twice daily for 1 week. She returned to 
South Africa on 1 November 2012 with a urinary catheter in situ (for 
ease of travel on the flight). On removal of the catheter the following 
day, her urine was noted to be turbid. She was, nevertheless, apyrexial 
and otherwise asymptomatic. There were no associated comorbid 
conditions. Urine dipstix revealed leucocyte esterase, prompting 
treatment with 3 doses of 3 g fosfomycin administered 2 days apart. 
A midstream urine specimen was sent to the laboratory.
Laboratory investigations
Urine microscopy revealed 10 red blood cells and 9 leucocytes/
high-power field. Culture revealed Enterobacter cloacae with the 
susceptibility pattern outlined in Table 1. Identification was confirmed 
using the automated Vitek 2 system (Biomerieux, Johannesburg, 
SA). Susceptibility testing was performed using the Kirby Bauer 
method and the Vitek 2 system. All susceptibility test results were 
interpreted using Clinical and Laboratory Standards Institute (CLSI) 
2012 guidelines,[4] except for tigecycline and colistin for which the 
2012 European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) breakpoints were used.[5] Carbapenem and tigecycline 
minimum inhibitory concentrations (MICs) were determined by 
using E-tests (Biomerieux, South Africa) on Mueller-Hinton agar. 
Carbapenemase activity was suggested by the Vitek 2 expert system 
and confirmed by a positive modified Hodge test (CLSI guidelines 
2012). A validated commercially available real-time PCR assay 
(Shanghai ZJ Bio-Tech) was used for the detection of New Delhi 
metallo-beta-lactamase 1 (NDM-1). DNA was extracted from 
culture, amplified and detected using a labelled primer/probe set. 
Inhibition was monitored by the use of an internal control. The 
isolate was confirmed NDM-1 positive. This result was verified by the 
National Institute for Communicable Diseases by multiplex real-time 
PCR using the LightCycler 480 Probes Master kit (Roche Diagnostics, 
USA). Repeat urine on 15 November 2012 showed no abnormalities 
and a negative culture.
Discussion
NDM-1 was first detected in an isolate of Klebsiella pneumoniae from 
a Swedish patient of Indian origin in 2008.[6] It was subsequently 
detected in Enterobacteriaceae in India, Pakistan, the UK, USA, 
Canada, Japan, Brazil and Africa.[7,8,10] The first documented report 
of NDM-1 in Enterobacteriacae in SA was from Gauteng in August 
2011.[3] The case presented here is the first documented case in 
KwaZulu-Natal, SA.
With increasing resistance among the Enterobacteriaceae to 
various classes of antimicrobial agents, carbapenems have formed 
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the backbone of treatment. The emergence of novel β-lactamases 
with direct carbapenem-hydrolysing activity has contributed to an 
increased prevalence of carbapenem-resistant Enterobacteriaceae 
(CRE). These are usually accompanied by resistance mechanisms to 
other classes of antibiotics, thereby posing an additional therapeutic 
challenge.[8] CREs are a significant threat for a number of reasons: the 
frequency with which they cause infections, the high mortality with 
which they are associated[9] and the potential for their widespread 
transmission via mobile genetic elements.[8] The NDM-1 gene found 
on a plasmid is highly transmissible to other bacteria. NDM-1-
positive bacteria are capable of colonising the gastro-intestinal 
tract of humans for prolonged periods and are spread through 
contamination of water and environmental surfaces.[6] The ease and 
frequency of international travel has contributed additionally to rapid 
global dissemination.
Current data suggest that recent hospitalisation in, and perhaps 
even travel to, the Indian subcontinent be identified as a risk factor 
for colonisation with the NDM-1-producing strain,[8,11] recognising 
that medical care is often sought by individuals visiting relatives in 
India and Pakistan. A recent case of NDM-1-producing Providencia 
rettgeri in an Australian who received elective plastic surgery in 
India illustrates this phenomenon.[10] Despite these factors, there 
are very few cases with a confirmed epidemiological link.[11] In the 
editorial by Coetzee et al., on the emergence of CREs in SA, the 
origin of the NDM-1s was not determined.[12] In the light of the KZN 
case, strong consideration should be given to screening patients 
(testing of rectal swabs for detection of NDM-1 carriage) with a 
history of recent hospitalisation in the Indian subcontinent who 
present for medical care. Given that NDM-1 is a globally emerging 
phenomenon, a case might be made for routine screening for CRE 
colonisation in patients after recent hospitalisation overseas and in 
those recently admitted to hospitals in Gauteng and Cape Town, 
since, following the first reported case in Gauteng, that outbreak 
has been ongoing.
It is also important to note that other molecular mechanisms 
of carbapenem resistance have been reported in SA, viz. OXA-48, 
KPC, VIM and GESs.[13] Early recognition and reporting provides an 
opportunity to establish national measures to prevent such isolates 
becoming endemic in healthcare settings. Owing to the limited 
therapeutic options available, early identification of CREs and 
timely isolation and infection control measures are key to curtailing 
the spread of these organisms. Concerns about carbapenemases 
justify a high index of suspicion in diagnostic laboratories and the 
routine screening of all clinically significant Enterobacteriaceae for 
susceptibility to carbapenem agents. Rapid detection is essential for 
patient management and prevention of further transmission, with 
the aim of limiting the public health impact of these extremely drug-
resistant strains.
Conclusion
To our knowledge, this is the first documented case of an NDM-1 
Enterobacteriacea in KZN and the first case in SA where a direct 
epidemiological link to the Indian subcontinent has been established. 
Since the detection of this isolate, other cases in several hospitals 
have been identified. Ongoing vigilance and strict infection control 
measures need to be maintained.
Table 1. Antimicrobial susceptibility test results: Enterobacter cloacae NDM-1 positive
Antimicrobial agents
Susceptibility test results
Vitek 2 Interpretation E-test Interpretation
MIC (μg/ml) S/I/R MIC (μg/ml) S/I/R
Ampicillin ≥32 R NT
Amoxycillin-clavulanic acid ≥32 R NT
Piperacillin-tazobactam ≥128 R NT
Cefepime ≥64 R NT
Ceftriaxone ≥64 R NT
Cefoxitin ≥64 R NT
Cefuroxime ≥64 R NT
Ceftazidime ≥64 R NT
Doripenem NT 16 R
Ertapenem ≥8 R NT
Imipenem ≥16 R 12 R
Meropenem ≥16 R 24 R
Gentamicin ≥16 R NT
Amikacin ≥32 R NT
Tigecycline* NT 0.5 S
Ciprofloxacin ≥4 R NT
Cotrimoxazole ≥320 R NT
Fosfomycin† NT NT
Colistin* ≤2 S NT
S = susceptible; I = intermediate; R = resistant; NT = not tested; MIC = minimum inhibitory concentration.
*EUCAST 2012 interpretive criteria.
†Susceptible by CLSI zone diameter interpretive criteria for E. coli.
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